Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an or… Read more
Market Cap & Net Worth: Bavarian Nordic A/S (BVNKF)
Bavarian Nordic A/S (PINK:BVNKF) has a market capitalization of $1.62 Billion ($1.62 Billion) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #5587 globally and #3276 in its home market, demonstrating a -14.53% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bavarian Nordic A/S's stock price $20.71 by its total outstanding shares 78269883 (78.27 Million).
Bavarian Nordic A/S Market Cap History: 2015 to 2025
Bavarian Nordic A/S's market capitalization history from 2015 to 2025. Data shows change from $3.27 Billion to $1.62 Billion (-4.80% CAGR).
Bavarian Nordic A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bavarian Nordic A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.38x
Bavarian Nordic A/S's market cap is 0.38 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
2.17x
Bavarian Nordic A/S's market cap is 2.17 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.27 Billion | $1.02 Billion | $59.43 Million | 3.20x | 54.96x |
| 2016 | $2.16 Billion | $1.01 Billion | $30.60 Million | 2.15x | 70.62x |
| 2017 | $2.30 Billion | $1.37 Billion | $181.34 Million | 1.68x | 12.70x |
| 2018 | $1.19 Billion | $500.62 Million | -$361.93 Million | 2.37x | N/A |
| 2019 | $1.56 Billion | $662.49 Million | -$346.78 Million | 2.36x | N/A |
| 2020 | $2.36 Billion | $1.85 Billion | $277.52 Million | 1.27x | 8.49x |
| 2021 | $3.25 Billion | $1.90 Billion | -$464.77 Million | 1.71x | N/A |
| 2022 | $2.35 Billion | $3.15 Billion | -$347.38 Million | 0.75x | N/A |
| 2023 | $2.05 Billion | $7.06 Billion | $1.48 Billion | 0.29x | 1.39x |
| 2024 | $2.15 Billion | $5.72 Billion | $987.98 Million | 0.38x | 2.17x |
Competitor Companies of BVNKF by Market Capitalization
Companies near Bavarian Nordic A/S in the global market cap rankings as of March 19, 2026.
Key companies related to Bavarian Nordic A/S by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Bavarian Nordic A/S Historical Marketcap From 2015 to 2025
Between 2015 and today, Bavarian Nordic A/S's market cap moved from $3.27 Billion to $ 1.62 Billion, with a yearly change of -4.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $1.62 Billion | -24.44% |
| 2024 | $2.15 Billion | +4.50% |
| 2023 | $2.05 Billion | -12.57% |
| 2022 | $2.35 Billion | -27.71% |
| 2021 | $3.25 Billion | +37.92% |
| 2020 | $2.36 Billion | +50.64% |
| 2019 | $1.56 Billion | +31.51% |
| 2018 | $1.19 Billion | -48.39% |
| 2017 | $2.30 Billion | +6.59% |
| 2016 | $2.16 Billion | -33.84% |
| 2015 | $3.27 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Bavarian Nordic A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.62 Billion USD |
| MoneyControl | $1.62 Billion USD |
| MarketWatch | $1.62 Billion USD |
| marketcap.company | $1.62 Billion USD |
| Reuters | $1.62 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.